Monocyte differentiation antigen CD14 and soluble CD163, a marker for monocyte activation, have been shown to be elevated in patients with COVID‐19 and may be potential biomarkers of disease progression (Gomez‐Rial et al., 2020; Messner et al., 2020). Here, CD163 is linked to COVID-19.